SKYE Stock Risk & Deep Value Analysis
Skye Bioscience Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SKYE Stock
We analyzed Skye Bioscience Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SKYE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SKYE Risk Analysis & Red Flags
What Could Go Wrong
The most immediate and severe risk is a Nasdaq delisting, triggered by the stockholders' equity falling below the $10 million minimum (currently $9.01M as of March 31, 2026). If Skye fails to submit an acceptable compliance plan by June 29, 2026, or cannot execute on it, the stock faces delisting, which would severely impair liquidity and access to capital.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Nasdaq Deficiency Notice: Stockholders' equity ($9.01M as of 3/31/2026) below $10M minimum, posing imminent delisting risk.
- ⚠
Significant Cash Burn: $10.0M cash burn in Q1 2026, with only $17.1M cash remaining, indicating short runway without new funding.
- ⚠
Widening Net Loss: Net loss increased 12.6% YoY to $12.5M in Q1 2026, reflecting increasing operational costs with no revenue.
- ⚠
Authorized Share Increase: Board approval to increase authorized common shares from 100M to 300M signals high probability of substantial future dilution.
Upcoming Risk Events
- 📅
Nasdaq Delisting (post-June 29, 2026, or post-Nov 9, 2026 if extended): Failure to meet stockholders' equity requirement or gain compliance plan acceptance.
- 📅
Unsuccessful Capital Raise (H2 2026): Inability to secure sufficient funding, leading to further cash crunch, deeper dilution, or operational shutdown.
- 📅
Negative Clinical Trial Data (Cohort 2 or future phases): Lack of efficacy or unexpected safety concerns for SBI-100, impacting pipeline viability.
When to Reconsider
- 🚪
Exit if Nasdaq provides a definitive delisting notice without a viable path to compliance.
- 🚪
Sell if cash balance falls below $10 million without a clear financing plan announced.
- 🚪
Reduce position if Cohort 2 clinical data for SBI-100 shows unexpected adverse events or fails to demonstrate adequate efficacy.
Unlock SKYE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Skye Bioscience Inc (SKYE) Do?
Market Cap
$25.09M
Sector
Healthcare
Industry
Biotechnology
Employees
16
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Visit Skye Bioscience Inc WebsiteInvestment Thesis
If Skye Bioscience can successfully navigate its current financial crisis, secure significant dilutive or non-dilutive funding (e.g., $50-100M+), resolve its Nasdaq compliance issue by June 29, 2026, and continue to generate positive clinical data for its SBI-100 program through Phase 2/3, then the company's novel therapeutic approach for glaucoma (and potentially obesity) could attract partnership interest or M&A, leading to a substantial re-rating from its current micro-cap status. This is bullish because the market is currently heavily discounting the clinical upside due to the severe financial and regulatory overhangs.
Is SKYE Stock Undervalued?
Unlock the full AI analysis for SKYE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SKYE Price Targets & Strategy
12-Month Target
$1.50
Bull Case
$3.00
Bear Case
$0.10
Valuation Basis
Speculative valuation based on successful capital raise (~$50M), Nasdaq compliance, and continued positive Phase 2a safety data, implying an eventual path to partnership, offsetting dilution.
Entry Strategy
Extremely high-risk entry only for speculative capital; consider small position below $0.50 if Nasdaq compliance plan is submitted and accepted.
Exit Strategy
Take profit on any significant news-driven spikes (e.g., successful financing, positive Phase 2 data) above $2.00; Stop loss at $0.30 if Nasdaq delisting fears escalate or further dilution announced without clear progress.
Portfolio Allocation
0.5% for aggressive risk tolerance only
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is SKYE Financially Healthy?
Valuation
P/E Ratio
1.00
Forward P/E
-0.54
EV/EBITDA
1.00
PEG Ratio
-0.05
Price/Book
1.53
Profitability
Gross Margin
39.29%
Operating Margin
-7.14%
Net Margin
-3.57%
Return on Equity
-217.27%
EPS
$-1.45
Balance Sheet
Current Ratio
3.30
Quick Ratio
3.24
Debt/Equity
0.03
Cash & Equivalents
$17.11M
Cash Flow
Operating Cash Flow
-$8.63M
Free Cash Flow
-$8.63M
EBITDA
-$57.33M
Other
Beta (Volatility)
2.95
Does SKYE Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Expanding
Moat Sources
1 Identified
Currently, the moat is nascent and relies solely on the successful clinical development and eventual regulatory approval of its novel drug candidates. If the drugs fail or are outcompeted, there is no inherent durability.
Moat Erosion Risks
- •Clinical Trial Failure: If SBI-100 fails to demonstrate efficacy or safety in later-stage trials, the IP loses much of its value.
- •Competitor Innovation: Larger pharmaceutical companies with greater resources could develop superior or similar treatments, eroding potential market share.
- •Lack of Funding: Inability to finance expensive clinical trials would prevent the company from capitalizing on its IP.
SKYE Competitive Moat Analysis
Sign up to see competitive advantages
SKYE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral/Bearish, reflecting high uncertainty and delisting fears, despite clinical progress.
Institutional Sentiment
Negative, likely characterized by minimal institutional interest given the micro-cap status and severe financial/regulatory risks.
Insider Activity (Form 4)
No specific Form 4 insider buying or selling activity was found in the provided research for the last 90 days. Therefore, no immediate signal from insiders.
Options Flow
Normal options activity for a micro-cap; lack of specific data suggests no unusual institutional positioning.
Earnings Intelligence
Next Earnings
2026-08-06 (Unconfirmed)
Surprise Probability
Medium
Historical Earnings Pattern
Likely highly volatile due to the clinical-stage nature and precarious financial position. Any perceived positive or negative news on funding or trials could lead to significant swings.
Key Metrics to Watch
Competitive Position
Top Competitor
Aerie Pharmaceuticals (acquired by Alcon for glaucoma pipeline; provides an example of successful glaucoma development)
Market Share Trend
Not applicable; pre-commercial.
Valuation vs Peers
Difficult to compare directly as Skye is pre-revenue and faces severe financial distress. Valued significantly below any commercial-stage peer, reflecting its early stage and high risk. Any valuation metrics would be non-comparable.
Competitive Advantages
- •Novel cannabinoid-derived therapeutic approach (SBI-100) as a potential new mechanism for glaucoma and other indications (obesity).
- •Proprietary IP surrounding its lead compounds and formulation.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive SKYE Stock Higher?
Near-Term (0-6 months)
- •Nasdaq compliance plan submission (by June 29, 2026): Acceptance of plan would temporarily resolve delisting risk.
- •Q2 2026 Earnings Report (estimated Aug. 6, 2026): Key focus on cash burn, updated cash position, and Nasdaq compliance status.
- •Clinical Update on Cohort 2 (SBI-100 for glaucoma, H2 2026): Favorable safety and preliminary efficacy data would further de-risk the program.
Medium-Term (6-18 months)
- •Successful Capital Raise (H2 2026 - H1 2027): Securing $50M-$100M+ to fund ongoing clinical development and resolve Nasdaq equity issues.
- •Initiation of Phase 2b/3 trial (late 2027): Progressing SBI-100 into later-stage trials for glaucoma, validating clinical trajectory.
- •Strategic Partnership Announcement (H2 2027): Partnership for SBI-100 development/commercialization, providing non-dilutive funding and validation.
Long-Term (18+ months)
- •Phase 3 Trial Completion and Positive Data (2029-2030): Successful completion of pivotal trials for SBI-100, paving the way for regulatory submission.
- •FDA Approval and Commercialization (2030-2031): Entry into the multi-billion dollar glaucoma market, generating initial product revenue.
- •Pipeline Expansion into Obesity/Metabolic Disorders (2028+): Advancement of a new drug candidate in the massive obesity market, diversifying revenue potential.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for SKYE?
- ✓
Watch Nasdaq compliance status: Any announcement of non-compliance or delisting would be a major negative.
- ✓
Watch cash balance: A significant dip below $15M without a financing announcement is critical.
- ✓
Watch SBI-100 Cohort 2 data: Positive efficacy or stronger safety profiles would be a key de-risking event.
Bull Case Analysis
Sign up free to see the bull case
Competing with SKYE
See how Skye Bioscience Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Skye Bioscience Inc SKYE | $25.1M | 3.8 | 1.0 | — | -3.6% | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Skye Bioscience Inc Makes Money
Skye Bioscience is a clinical-stage pharmaceutical company focused on developing novel cannabinoid-derived therapeutics for unmet medical needs. Its primary focus is on SBI-100, which is currently in Phase 2a clinical trials for the treatment of glaucoma, with potential expansion into obesity and related metabolic conditions. The company currently generates no revenue and relies entirely on external financing to fund its expensive research and development activities, with future revenue expected from drug sales upon regulatory approval or from licensing agreements with larger pharmaceutical partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Skye Bioscience Inc (SKYE)?
As of June 3, 2026, Skye Bioscience Inc has a DVR Score of 3.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Skye Bioscience Inc?
Skye Bioscience Inc's market capitalization is approximately $25.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Skye Bioscience Inc use?
SKYE is the ticker symbol for Skye Bioscience Inc. The company trades on the NGM.
What is the risk level for SKYE stock?
Our analysis rates Skye Bioscience Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SKYE?
Skye Bioscience Inc currently has a price-to-earnings (P/E) ratio of 1.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is SKYE stock profitable?
Skye Bioscience Inc has a profit margin of -3.6%. The company is currently unprofitable.
How often is the SKYE DVR analysis updated?
Our AI-powered analysis of Skye Bioscience Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SKYE (Skye Bioscience Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.